Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec:62 Suppl 2:S79-S94.
doi: 10.1002/jcph.2141.

Clinical Pharmacology Considerations on Recombinant Adeno-Associated Virus-Based Gene Therapy

Kefeng Sun  1 , Michael Z Liao  2
Affiliations
Review

Clinical Pharmacology Considerations on Recombinant Adeno-Associated Virus-Based Gene Therapy

Kefeng Sun et al. J Clin Pharmacol. 2022 Dec.

Abstract

Recombinant adeno-associated virus (AAV) is currently the most widely used platform for in vivo gene therapy. Clinical pharmacology is a central field for AAV gene therapy, represented by the pillars of pharmacokinetics, pharmacodynamics/efficacy, and safety. In this review, we provide a comprehensive summary of clinical pharmacology considerations for recombinant AAV. The main topics covered are biodistribution and shedding, dose-exposure-response relationship, safety, immune and stress response, and clinical dose selection strategies. We highlight how the cumulative knowledge of AAV gene therapy could help with guiding clinical trial design and assessing and mitigating risks, as well as planning and executing pharmacokinetic/pharmacodynamic /safety data analyses. In addition, we discuss the major gaps and areas of growth in clinical pharmacology understanding of recombinant AAV. These include the mechanisms of the durability of treatment response and variability in biodistribution, transduction, and immunogenicity, as well as a potential influence on AAV's safety and efficacy profiles by drug product characteristics and patient intrinsic/extrinsic factors.

Keywords: adeno-associated virus (AAV); biodistribution; dose-exposure-response; durability; gene therapy; immune response; pharmacokinetics/pharmacodynamics (PK/PD).

PubMed Disclaimer

References

    1. U.S. Food and Drug Administration. Statement from FDA Commissioner Scott Gottlieb, M.D. and Peter Marks, M.D., Ph.D., Director of the Center for Biologics Evaluation and Research on new policies to advance development of safe and effective cell and gene therapies. Published 2019. Accessed March 7, 2022. https://www.fda.gov/news-events/press-announcements/statement-fda-commis....
    1. Upstaza™ Granted Marketing Authorization by European Commission as First Disease-Modifying Treatment for AADC Deficiency. Published 2022. Accessed July 25, 2022. https://www.prnewswire.com/news-releases/upstaza-granted-marketing-autho....
    1. Zhao Z, Anselmo AC, Mitragotri S. Viral vector-based gene therapies in the clinic. Bioeng Transl Med. 2022;7(1):e10258.
    1. Kuzmin DA, Shutova MV, Johnston NR, et al. The clinical landscape for AAV gene therapies. Nat Rev Drug Discov. 2021;20(3):173-174.
    1. Chan YK, Wang SK, Chu CJ, et al. Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses. Sci Transl Med. 2021;13(580), https://www.science.org/doi/10.1126/scitranslmed.abd3438

LinkOut - more resources